ValueQ4, 24TTMSelling/general/admin expenses——Research & development——Operating income——Non-Operating Income, Total——Interest expense, net of interest capitalized——Non-Operating Income, excl. Interest Expenses——Unusual income/expense——Pretax income10.55 M90.68 MEquity in earnings——Taxes——Non-controlling/minority interest——After tax other income/expense——Net income before discontinued operations10.55 M90.68 MDiscontinued operations——Net income10.55 M90.68 MDilution adjustment——Preferred dividends——Diluted net income available to common stockholders10.55 M90.68 MBasic earnings per share (Basic EPS)——Diluted earnings per share (Diluted EPS)0.121.05Average basic shares outstanding89.53 M347.92 MDiluted shares outstanding89.53 M347.92 MEBITDA——EBIT——Cost of revenue——Other cost of goods sold——Depreciation & amortization (cash flow)——
Compugen Ltd
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.